The chemical structure for betamethasone sodium phosphate and betamethasone acetate is as follows:

![Chemical structure of betamethasone sodium phosphate](attachment:image.png)

**DESCRIPTION**

Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is a sterile ophthalmic suspension containing 3 mg/mL betamethasone sodium phosphate and 2 mg/mL betamethasone acetate, in 1 mL, 2 mL, and 5 mL multi-dose vials. The chemical structures for betamethasone sodium phosphate and betamethasone acetate are as follows:

Betamethasone sodium phosphate is in a 22-membered ring with a 17β-β-methyl group that enhances the anti-inflammatory action of the molecule. The chemical structure is CH₃(CH₂)₄C⁶H₄(OH)CH₂CH₂CH₂CH₂(OH)CH₂CH₂OCH₂CH₃.

Betamethasone acetate is a 4-diene-3,20-dione 21-acetate.

**USES**

Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated for the treatment of active ocular herpes simplex.

**DOSAGE AND ADMINISTRATION**

For use as a sterile ophthalmic suspension, 1 drop (0.05 mL) to 2 drops (0.1 mL) of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is applied to the affected eye(s) twice a day. The eyes should be cleansed prior to each instillation to ensure uniform contact of the suspension with the ocular surface. The eyes should be closed after administration.

**RECOMMENDATIONS**

- **Allergic States**
  - For the treatment of allergic states, Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as follows:

  - **Dermatologic Diseases**
    - For the treatment of dermatomyositis, polymyositis, and rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, osteoarthritis.

  - **Endocrine Disorders**
    - For suppression of the pituitary-adrenal axis in the treatment of systemic lupus erythematosus.

  - **Gastrointestinal**
    - For the treatment of inflammatory bowel disease.

- **Miscellaneous**
  - For the treatment of idiopathic eosinophilic pneumonias, symptomatic sarcoidosis.

- **Fungal Infections**
  - For the treatment of fungal infections.

**ADVERSE REACTIONS**

Adverse reactions may include:

- **Ocular**
  - Decreased intraocular pressure, increased intraocular pressure, irritation, burning, redness, itching, sensitivity.

- **Systemic**
  - Glucocorticosteroid insufficiency after withdrawal of systemic corticosteroids.

- **Other**
  - Systemic effects such as weight gain, fluid retention, hypertension.

**CONTRAINDICATIONS**

- Corticosteroids are contraindicated in patients with active or latent tuberculosis.

**WARNINGS**

- Patients with active tuberculosis should not receive corticosteroids.

**PRECAUTIONS**

- Corticosteroids may affect the results of tests for sugar in the urine or blood.

**REPRODUCTION**

Pregnancy Category C: Use only if clearly needed.

**NURSING MOTHERS**

Corticosteroids are not recommended for use in nursing mothers.

**REFERENCES**

For a complete list of references, please refer to the full prescribing information.
Betamethasone Sodium Phosphate and Acetate

FOR INTRA-ARTICULAR USE ONLY

Betamethasone Sodium Phosphate and Acetate Injectable Suspension is a corticosteroid suspension for synovial membrane infiltration or intra-articular administration for relief of the inflammatory and/or pain components of various non-infectious joint conditions. Osteoarthritis, rheumatoid arthritis, and acute exacerbations of chronic bursitis are among the conditions for which relief may be obtained with the use of Betamethasone Sodium Phosphate and Acetate Injectable Suspension.

Intra-articular Injection

Betamethasone Sodium Phosphate and Acetate Injectable Suspension may be used for the treatment of arthritic conditions and other inflammatory conditions about large joints, such as the knee, hip, shoulder, ankle, and elbow. It may be administered intra-articularly or directly into bursae and tendon sheaths. Because of the high concentration of corticosteroid in this injectable suspension, great care should be exercised in the use of this preparation to avoid the complications associated with intra-articular injection of corticosteroids.

Injection of Corticosteroids

Betamethasone Sodium Phosphate and Acetate Injectable Suspension is injected intradermally (not intramuscularly) for testing only. The usual dosage is 0.1 mL of the injectable suspension, which contains 0.5 mg of Betamethasone Sodium Phosphate and 0.5 mg of Betamethasone Acetate. If the patient is sensitive to the corticosteroid, anaphylactoid reactions (including widespread urticaria), fever, and toxic symptoms may develop. If the reaction is severe, immediately discontinue the use of the corticosteroid and institute appropriate measures to treat the reaction.

Injection of Corticosteroids in the Epidural Space

Betamethasone Sodium Phosphate and Acetate Injectable Suspension is used for the treatment of certain conditions in the epidural space, such as ankylosing spondylitis, spondylolisthesis, degenerative disc disease, and spinal stenosis. For these conditions, an injection may be made either into the subarachnoid space or directly into the spinal canal with the use of an epidural needle. Injections may be repeated at intervals of 2 to 4 weeks. When used in the epidural space, Betamethasone Sodium Phosphate and Acetate Injectable Suspension may cause local irritation at the injection site and may produce transient systemic symptoms, including fever, chills, and neck stiffness.

Intra-articular Injection

Betamethasone Sodium Phosphate and Acetate Injectable Suspension may be used for the treatment of arthritic conditions and other inflammatory conditions about large joints, such as the knee, hip, shoulder, ankle, and elbow. It may be administered intra-articularly or directly into bursae and tendon sheaths. Because of the high concentration of corticosteroid in this injectable suspension, great care should be exercised in the use of this preparation to avoid the complications associated with intra-articular injection of corticosteroids.

Injection of Corticosteroids

Betamethasone Sodium Phosphate and Acetate Injectable Suspension is injected intradermally (not intramuscularly) for testing only. The usual dosage is 0.1 mL of the injectable suspension, which contains 0.5 mg of Betamethasone Sodium Phosphate and 0.5 mg of Betamethasone Acetate. If the patient is sensitive to the corticosteroid, anaphylactoid reactions (including widespread urticaria), fever, and toxic symptoms may develop. If the reaction is severe, immediately discontinue the use of the corticosteroid and institute appropriate measures to treat the reaction.

Injection of Corticosteroids in the Epidural Space

Betamethasone Sodium Phosphate and Acetate Injectable Suspension is used for the treatment of certain conditions in the epidural space, such as ankylosing spondylitis, spondylolisthesis, degenerative disc disease, and spinal stenosis. For these conditions, an injection may be made either into the subarachnoid space or directly into the spinal canal with the use of an epidural needle. Injections may be repeated at intervals of 2 to 4 weeks. When used in the epidural space, Betamethasone Sodium Phosphate and Acetate Injectable Suspension may cause local irritation at the injection site and may produce transient systemic symptoms, including fever, chills, and neck stiffness.

Intra-articular Injection

Betamethasone Sodium Phosphate and Acetate Injectable Suspension may be used for the treatment of arthritic conditions and other inflammatory conditions about large joints, such as the knee, hip, shoulder, ankle, and elbow. It may be administered intra-articularly or directly into bursae and tendon sheaths. Because of the high concentration of corticosteroid in this injectable suspension, great care should be exercised in the use of this preparation to avoid the complications associated with intra-articular injection of corticosteroids.

Injection of Corticosteroids

Betamethasone Sodium Phosphate and Acetate Injectable Suspension is injected intradermally (not intramuscularly) for testing only. The usual dosage is 0.1 mL of the injectable suspension, which contains 0.5 mg of Betamethasone Sodium Phosphate and 0.5 mg of Betamethasone Acetate. If the patient is sensitive to the corticosteroid, anaphylactoid reactions (including widespread urticaria), fever, and toxic symptoms may develop. If the reaction is severe, immediately discontinue the use of the corticosteroid and institute appropriate measures to treat the reaction.

Injection of Corticosteroids in the Epidural Space

Betamethasone Sodium Phosphate and Acetate Injectable Suspension is used for the treatment of certain conditions in the epidural space, such as ankylosing spondylitis, spondylolisthesis, degenerative disc disease, and spinal stenosis. For these conditions, an injection may be made either into the subarachnoid space or directly into the spinal canal with the use of an epidural needle. Injections may be repeated at intervals of 2 to 4 weeks. When used in the epidural space, Betamethasone Sodium Phosphate and Acetate Injectable Suspension may cause local irritation at the injection site and may produce transient systemic symptoms, including fever, chills, and neck stiffness.

Intra-articular Injection

Betamethasone Sodium Phosphate and Acetate Injectable Suspension may be used for the treatment of arthritic conditions and other inflammatory conditions about large joints, such as the knee, hip, shoulder, ankle, and elbow. It may be administered intra-articularly or directly into bursae and tendon sheaths. Because of the high concentration of corticosteroid in this injectable suspension, great care should be exercised in the use of this preparation to avoid the complications associated with intra-articular injection of corticosteroids.

Injection of Corticosteroids

Betamethasone Sodium Phosphate and Acetate Injectable Suspension is injected intradermally (not intramuscularly) for testing only. The usual dosage is 0.1 mL of the injectable suspension, which contains 0.5 mg of Betamethasone Sodium Phosphate and 0.5 mg of Betamethasone Acetate. If the patient is sensitive to the corticosteroid, anaphylactoid reactions (including widespread urticaria), fever, and toxic symptoms may develop. If the reaction is severe, immediately discontinue the use of the corticosteroid and institute appropriate measures to treat the reaction.

Injection of Corticosteroids in the Epidural Space

Betamethasone Sodium Phosphate and Acetate Injectable Suspension is used for the treatment of certain conditions in the epidural space, such as ankylosing spondylitis, spondylolisthesis, degenerative disc disease, and spinal stenosis. For these conditions, an injection may be made either into the subarachnoid space or directly into the spinal canal with the use of an epidural needle. Injections may be repeated at intervals of 2 to 4 weeks. When used in the epidural space, Betamethasone Sodium Phosphate and Acetate Injectable Suspension may cause local irritation at the injection site and may produce transient systemic symptoms, including fever, chills, and neck stiffness.